Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jul;14(3):224-30.
doi: 10.1080/08998280.2001.11927767.

Provider and health care system response to a bioterrorist attack

J D Malone  1
Affiliations

Provider and health care system response to a bioterrorist attack

J D Malone. Proc (Bayl Univ Med Cent). 2001 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Federal analytical capabilities deployed at the 1996 Summer Olympic Games in Atlanta, Georgia. Reprinted with permission from Ember LR. FBI takes lead in developing counterterrorism effort. Chem Eng News 1996(Nov 4):10–16. Copyright 1996 American Chemical Society.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

Anthrax

    1. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A. 1993;90:2291–2294. - PMC - PubMed
    1. Bartlett JG, Dowell SF, Mandell LA, File TM, Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31:347–382. - PMC - PubMed
    1. [Pneumonia in the context of bioterrorism] Centers for Disease Control and Prevention Bioterrorism alleging use of anthrax and interim guidelines for management—United States, 1998. MMWR Morb Mortal Wkly Rep. 1999;48:69–74. - PubMed
    1. English JF, Cundiff MY, Malone JD, Pfeiffer JA, Bell M, Steele L, Miller M. Bioterrorism readiness plan: a template for healthcare facilities. APIC Bioterrorism Task Force/CDC Hospital Infections Program Bioterrorism Working Group. Available at http://www.apic.org. Accessed April 13, 1999.
    1. Friedlander A. Anthrax. In: Zajtchuk R, Bellamy RF, editors. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General, US Department of the Army; 1997. pp. 467–478.

Anthrax vaccine

    1. Anthrax vaccine adsorbed [package insert]. Lansing, Mich: Michigan Department of Public Health, 1987.
    1. Brachman PS, Friedlander AM. Anthrax. In: Plotkin SA, Mortimer EA, editors. Vaccines. 2nd ed. Philadelphia: WB Saunders Co; 1994. pp. 729–739.
    1. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of human anthrax vaccine. Am J Public Health. 1962;52:632–645. - PMC - PubMed
    1. Broster MG, Hibbs SE. Protective efficacy of anthrax vaccines against aerosol challenge. Salisbury Med Bull Suppl. 1990;68:91–92.
    1. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, Ivins BE, Lowe RJ, Howe GB, Mikesell P, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993;167:1239–1243. - PubMed

Anthrax pathogenesis

    1. Fritz DL, Jaax NKI, Lawrence WB, Davis KJ, Pitt ML, Ezzell JW, Friedlander AM. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest. 1995;73:691–691. - PubMed
    1. Hanna PC, Acosta D, Collier RJ. On the role of macrophages in anthrax. Proc Natl Acad Sci U S A. 1993;90:10198–10198. - PMC - PubMed
    1. Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A. 1982;79:3162–3162. - PMC - PubMed
    1. Lincoln RE, Fish DC. Anthrax toxin. In: Montie TC, Kadis S, Aji SJ, editors. Microbial Toxins, vol. 3, Bacterial Protein Toxins. New York: Academic Press; 1970. pp. 316–414.
    1. Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bact. 1957;73:485–485.

Anthrax epidemiology

    1. Carr EA, Rew R. Recovery of Bacillus anthracis from the nose and throat of apparently healthy workers. J Infect Dis. 1957:169–171. - PubMed
    1. Dahlgren C, Buchanan LM, Decker HM, Freed SW, Philips CR, Brachman PS. Bacillus anthracis aerosols in goat hair processing mills. Am J Hyg. 1960;72:24–24. - PubMed
    1. Watson A, Keir D. Information on which to base assessments of risk from environments contaminated with anthrax spores. Epidemiol Infect. 1994;133:479–479. - PMC - PubMed

Botulism

    1. Franz D. Defense against toxin weapons. In: Zajtchuk R, Bellamy RF, editors. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General, US Department of Army; 1997. pp. 603–619.
    1. Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response. A public health strategy for a global challenge. JAMA. 1997;278:433–433. - PubMed
    1. Medical Defense Against Biological Warfare Agents [course text]. Fort Detrick, Md: USAMRIID, 1997.

Plague

    1. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM., Jr Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399–411. - PubMed
    1. McGovern TW, Friedlander AM. Plague. In: Zajtchuk R, Bellamy RF, editors. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General, US Department of the Army; 1997. pp. 479–502.

Smallpox

    1. Board WJ, Miller J. Smallpox stocks hidden, report says, Iraq, N. Korea, Russia cited by intelligence assessment. New York Times, reprinted in Cleveland Plain Dealer, June 13, 1999.
    1. DeClercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res. 1987;8:261–272. - PubMed
    1. Fenner F. Poxviruses. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. New York: Churchill Livingstone; 1997. pp. 357–367.
    1. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl T, Russell PK, Tonat K. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA. 1999;281:2127–2137. - PubMed
    1. Huggins JW, Robertson M, Kefauver D, Laughlin C. Potential antiviral therapeutics for smallpox and other pox virus infections. Presented at the 11th International Meeting on Poxviruses and Iridovirus, May 4–9,1996, Toledo, Spain.

Quinolone utilization

    1. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis. 1997;25:1196–1204. - PubMed
    1. Doganay M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis. 1991;23:333–335. - PubMed
    1. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use—safety report. Pediatr Infect Dis J. 1997;16:127–129. - PubMed
    1. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 2000;31(Suppl 2):S24–S28. - PubMed
    1. Kohlhepp SJ, Grunkemeir G, Leggett JE, Dworkin RJ, Slaughter SE, Gilbert DN. Phenotypic resistance of penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae after single and multiple in vitro exposures to ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin and trovafloxacin [abstract 97]. 38th Annual Meeting, Infectious Diseases Society of America, New Orleans, La, 2000.

Psychological response

    1. Burgess JL, Kirk M, Borron SW, Cisek J. Emergency department hazardous materials protocol for contaminated patients. Ann Emerg Med. 1999;34:205–212. - PubMed
    1. DiGiovanni C., Jr Domestic terrorism with chemical or biological agents: psychiatric aspects. Am J Psychiatry. 1999;156:1500–1505. - PubMed
    1. Fullerton CS, Ursano RJ. Behavioral and psychological responses to chemical and biological warfare. Mil Med. 1990;155:54–59. - PubMed
    1. Holloway HC, Norwood AE, Fullerton CS, Engel CC, Jr, Ursano RJ. The threat of biological weapons. Prophylaxis and mitigation of psychological and social consequences. JAMA. 1997;278:425–427. - PubMed
    1. Kline NA, Dow BM, Brown SA, Matloff JL. Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder. Am J Psychiatry. 1994;151:621. - PubMed

Emergency response

    1. Cieslak TJ, Christopher GW, Kortepeter MG, Rowe JR, Pavlin JA, Culpepper RC, Eitzen EM., Jr Immunization against potential biological warfare agents. Clin Infect Dis. 2000;30:843–850. - PubMed
    1. Crosby AW. America's Forgotten Pandemic. Cambridge, UK: Cambridge University Press; 1998.
    1. Diamond J. Guns, Germs, and Steel, the Fates of Human Societies. New York: WW Norton; 1999.
    1. Henderson DA. Weapons for the future. Lancet. 1999;354(Suppl S4):64. - PubMed
    1. Higgins JA, Ibrahim MS, Knauert FK, Ludwig GV, Kijek TM, Ezzell JW, Courtney BC, Henchal EA. Sensitive and rapid identification of biological threat agents. Ann N Y Acad Sci. 1999;894:130–148. - PubMed

LinkOut - more resources